These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 23876043)
1. New paradigms for treatment-resistant depression. Zarate C; Duman RS; Liu G; Sartori S; Quiroz J; Murck H Ann N Y Acad Sci; 2013 Jul; 1292():21-31. PubMed ID: 23876043 [TBL] [Abstract][Full Text] [Related]
2. Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back. Murck H J Psychiatr Res; 2013 Jul; 47(7):955-65. PubMed ID: 23541145 [TBL] [Abstract][Full Text] [Related]
3. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040 [TBL] [Abstract][Full Text] [Related]
4. Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. Chaturvedi HK; Bapna JS; Chandra D Indian J Physiol Pharmacol; 2001 Apr; 45(2):199-207. PubMed ID: 11480226 [TBL] [Abstract][Full Text] [Related]
5. Blocking NMDA receptor at rest: a possible alleviation of depression. Lu W Acta Pharmacol Sin; 2011 Sep; 32(9):1087-8. PubMed ID: 21804573 [No Abstract] [Full Text] [Related]
7. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Maeng S; Zarate CA Curr Psychiatry Rep; 2007 Dec; 9(6):467-74. PubMed ID: 18221626 [TBL] [Abstract][Full Text] [Related]
8. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Miller OH; Yang L; Wang CC; Hargroder EA; Zhang Y; Delpire E; Hall BJ Elife; 2014 Oct; 3():e03581. PubMed ID: 25340958 [TBL] [Abstract][Full Text] [Related]
9. Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus. Elhussiny MEA; Carini G; Mingardi J; Tornese P; Sala N; Bono F; Fiorentini C; La Via L; Popoli M; Musazzi L; Barbon A Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110033. PubMed ID: 32640261 [TBL] [Abstract][Full Text] [Related]
10. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Gerhard DM; Wohleb ES; Duman RS Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424 [TBL] [Abstract][Full Text] [Related]
11. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285 [TBL] [Abstract][Full Text] [Related]
12. Ketamine and other glutamate receptor modulators for depression in adults. Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901 [TBL] [Abstract][Full Text] [Related]
13. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Dale E; Bang-Andersen B; Sánchez C Biochem Pharmacol; 2015 May; 95(2):81-97. PubMed ID: 25813654 [TBL] [Abstract][Full Text] [Related]
14. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563 [TBL] [Abstract][Full Text] [Related]
15. Ketamine for Treatment-Resistant Depression: a New Advocate. Pérez-Esparza R Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013 [TBL] [Abstract][Full Text] [Related]
16. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431 [TBL] [Abstract][Full Text] [Related]
17. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB; Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481 [TBL] [Abstract][Full Text] [Related]
18. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061 [TBL] [Abstract][Full Text] [Related]
19. Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats. Hillhouse TM; Negus SS Eur J Pain; 2016 Sep; 20(8):1229-40. PubMed ID: 26914635 [TBL] [Abstract][Full Text] [Related]
20. The role of eEF2 kinase in the rapid antidepressant actions of ketamine. Suzuki K; Monteggia LM Adv Pharmacol; 2020; 89():79-99. PubMed ID: 32616215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]